Ann Thorac Surg 2001;71:47-48
© 2001 The Society of Thoracic Surgeons
Invited commentary: original article: cardiovascular
Invited commentary
Richard A. Hopkins, MDa,
Diane HoffmanKim, PhDb,
Mary S. Maish, MDc
a Professor and Chief, Cardiothoracic Surgery, Brown University School of Medicine, Director, Collis Cardiac Surgical Research Laboratory, Rhode Island Hospital, The Miriam Hospital, Hasbro Childrens Hospital, Providence, RI 02906, USA
b Assistant Professor, Department of Surgery, Division of Cardiac Surgery, Brown University School of Medicine, Lead Scientist, Collis Cardiac Surgical Research Laboratory, Providence, RI 02906, USA
c Roddy Scholar in Cardiac Surgery Research, Collis Cardiac Surgical Laboratory, Department of Surgery, Brown University School of Medicine, Providence, RI 02906, USA
e-mail: rahopkins@lifespan.org
This study by Shaddy and colleagues from Primary Childrens Medical Center in Salt Lake City is extraordinarily interesting and despite the low number of patients involved is a significant contribution to the evolving literature on immunology of cryopreserved homograft valve conduit transplants. The first point of interest is how difficult this study was to pursue given the potential for significant complications. One-third of the prospective study patients (including parents) approached, declined to take part in the study. Of the 20 patients actually entered into the study, only 13 completed a course of Azathioprine or . . . [Full Text of this Article]
Related Article
-
Prospective randomized trial of azathioprine in cryopreserved valved allografts in children
- Robert E. Shaddy, Linda M. Lambert, Thomas C. Fuller, Tracie Profaizer, Dixie D. Thompson, Shawna I. Baker, Karen A. Osborne, and John A. Hawkins
Ann. Thorac. Surg. 2001 71: 43-47.
[Abstract]
[Full Text]
[PDF]
Copyright © 2001 by The Society of Thoracic Surgeons.